Publications

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Comparative Activity of Meropenem-Vaborbactam and Ceftazidime-Avibactam Against Multidrug-Resistant Enterobacter cloacae from Hospitals in Europe and United States. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Ceftibuten-Avibactam against Clinical Isolates of Enterobacterales Producing Clinically Relevant Beta-Lactamases. Lead author: HS SAder presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Ceftaroline and Comparator Agents against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against Gram-Negative Bacteria Isolated from Bloodstream and Complicated Urinary Tract Infections in Europe, Asia, and Latin America (2019-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Occurrence of β-Lactamases among Enterobacterales Isolated from United States Hospitals: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused by Escherichia coli and Staphylococcus saprophyticus Collected Worldwide between 2019-2020. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Plazomicin against Multidrug-resistant Enterobacterales: Results from 3 Years of Surveillance in Hospitals in the United States (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-Ocrtober 3, Virtual Conference

Antimicrobial Susceptibility of Gram-negative Organisms from Southeast Asia. Lead author: H Sader presented at 13th International Symposium on Antimicrobial Agents and Resistance (ISAAR 2021), September 9-10, 2021, Virtual Conference
Poster #0323

Intermethod Comparability Analyses of Gepotidacin Antimicrobial Susceptibility Tests Using Over 3,600 Globally-collected Clinical Isolates. Lead author: SJR Arends presented at World Microbe Forum, 20-24 June 2021, Virtual Conference

Current Epidemiology and Activity of Gepotidacin and Comparator Agents Against Escherichia coli Surveillance Isolates Causing Urinary Tract Infections in the Unites States. Lead author: RE Mendes presented at World Microbe Forum, 20-24 June 2021, Virtual Conference

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalised with Bacterial Pneumonia in Western Europe and Eastern Europe: Results from the SENTRY Program (2018-2020). Lead author: H Sader presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #718

Antimicrobial Activities of Cefepime, Meropenem, Aztreonam, and Piperacillin Combined with Nacubactam against Molecularly Characterized Enterobacterales Collected Worldwide. Lead author: HS Sader presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #893

Activity of Meropenem-Vaborbactam and Comparators against European Carbapenem-Resistant Enterobacterales Isolates without a Carbapenemase. Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster # 1047

Activity of Meropenem-Vaborbactam and Comparators against Pseudomonas aeruginosa Isolates from Patients with Pneumonia in European Hospitals. Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster # 1048

Oritavancin Activity against Gram-Positive Pathogens causing Bone and Joint Infections In European Medical Centres (2015-2019). Lead author: CG Carvalhaes presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1626

Evaluation of Pleuromutilins Resistance Mechanisms Among Surveillance Clinical Isolates: Results from the Worldwide Surveillance Program for Lefamulin in 2019. Lead author: RE Mendes, presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #2146

Activity of Cefiderocol and Comparators against US Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, Including Carbapenem-Resistant Isolates. Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1606

Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017-2019). by Carvalhaes CG, Sader HS, Rhomberg PR and Mendes RE. published in Int. J. Infect. Dis. 2021; 107: 92-100

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U. S. gram-negative bacterial surveillance isolates (2012-2018). by Shortridge D, Carvalhaes CG, Streit JM and Flamm RK. published in Diag. Microbio. Infect. Dis. 2021; 100 (1): 11530

Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by species. by Sader HS, Carvalhaes CG, Streit JM, Arends SJR and Mendes RE. published in J Glob Antimicrob Resist. 2021; 24: 48-52

Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010-2019). by Sader HS, Carvalhaes CG and Mendes RE. published in Int. J. Infect. Dis. 2021; 102: 524-528

Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): Therapeutic options for multidrug-resistant bacteria. by Sader HS, Castanheira M, Streit JM, Carvalhaes CG and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2020; 98 (2): 115108

Update on the activity of delafloxacin on acute bacterial skin and skin structure infection isolates from European hospitals (2014-2019). by Shortridge D, Pfaller MA, Streit JM and Flamm RK. published in J. Glob. Antimicrob. Resist. 2020; 23: 278

Activity of Meropenem-Vaborbactam and Comparators Against Globally Disseminated Klebsiella pneumoniae Sequence Type 258. Lead Author: Lalitagauri Deshpande. Presented at IDWeek2020.

Poster #1589

Antimicrobial Activity of Dalbavancin against Clinical Isolates of Coagulase-Negative Staphylococci (CoNS) from United States and Europe Stratified by Species. Lead Author: Helio Sader. Presented at IDWeek 2020.

Poster #1449

Bloodstream Infections in the United States and Europe: Etiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2016-2019). Lead Author: Helio Sader. Presented at IDWeek 2020. 

Presentation #37

Antimicrobial Activity of Gepotidacin against Clinical Isolates of Escherichia coli and Staphylococcus saprophyticus Collected Worldwide in 2019. Lead Author: SJ Ryan Arends. Presented at IDWEEK 2020.

Poster #1262

Oritavancin Activity against Staphylococcus aureus Isolates Causing Bone and Joint Infection in European Hospitals (2010-2019). Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #327

Antimicrobial Activity of Aztreonam-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia in 2019. Lead author: HS Sader, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1261

Activity of meropenem-vaborbactam and single-agent comparators against Enterobacterales isolates, including KPC-producing isolates, from European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-2019). Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1590

Vancomycin Resistance in Enterococcus faecium Clinical Isolates Responsible for Bloodstream Infections in US Hospitals Over Ten Years (2010-2019) and Activity of Oritavancin. Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1629

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18. by Sader HS, Carvalhaes CG, Duncan LR, Flamm RK and Shortridge D. published in J. Antimicrob. Chemother. 2020; 75 (10): 2907-2913

Antimicrobial activity of ceftazidime-avibactam, ceftolozane-tazobactam and comparators tested against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States medical centers in 2016-2018. by Sader HS, Carvalhaes CG, Streit JM, Doyle TB and Castanheira M. published in Microb. Drug Resist. 2021; 27 (3): 342-349

Antimicrobial activity of ceftolozane-tazobactam and comparators against clinical isolates of Haemophilus influenzae from the United States and Europe. by Sader HS, Carvalhaes CG, Duncan LR and Shortridge D. published in Antimicrob. Agents Chemother. 2020;64 (5): e00211

Assessment of tedizolid in vitro activity and resistance mechanisms against a collection of Enterococcus spp. causing invasive infections, including isolates requiring an optimized dosing strategy for daptomycin from U.S. and European medical centers, 2016 to 2018. by Carvalhaes CG, Sader HS, Flamm RK, Streit JM and Mendes RE. published in Antimicrob. Agents Chemother. 2020; 64 (4): e00175

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2015-2017) P. aeruginosa isolates from a global surveillance program. by Shortridge D, Pfaller MA, Streit JM and Flamm RK. published in J. Glob. Antimicrob. Resist. 2019; 21: 60-64

Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide by Sader HS, Rhomberg PR, Duncan LR, Locher HH, Dale GE and Flamm RK. published in J. Antimicrob. Chemother. 2020; 75 (6): 1518-1524

Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016. by Duncan LR, Smith CJ, Flamm RK and Mendes RE. published in J. Glob. Antimicrob. Resist. 2020; 20: 118-123

Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates Collected from US Medical Centers in 2016-2018. Lead author: HS Sader. This poster was originally intended for presentation at ECCMID 2020, which was canceled due to the COVID-19 pandemic. The corresponding accepted abstract can be found in the 30th ECCMID abstract book under abstract 473.
Poster #P3598

Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016-2018. by Pfaller MA, Huband MD, Shortridge D and Flamm RK published in Antimicrobial agents and chemotherapy., 2020: 64 (5); e02488

Antimicrobial activity of telavancin tested in vitro against a global collection of gram-positive pathogens, including multidrug-resistant isolates (2015-2017). by Duncan LR, Sader HS, Huband MD, Flamm RK and Mendes RE published in Microb. Drug Resist.: in press, 2020.

Antimicrobial activity of cefoperazone-sulbactam tested against gram-negative organisms from Europe, Asia-Pacific, and Latin America. by Sader HS, Carvalhaes CG, Streit JM, Castanheira M and Flamm RK published in Int. J. Infect. Dis. 2020; 91: 32-37

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres. by Sader HS, Mendes RE, Pfaller MA and Flamm RK. published in J. Antimicrob. Chemother. 2019; 74 (5): 1306-1310

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2015-2017) P. aeruginosa isolates from a global surveillance program. by Shortridge D, Pfaller MA, Streit JM and Flamm RK published in J. Glob. Antimicrob. Resist.: in press, 2019.

Antimicrobial Activity of the Novel β-Lactam Enhancer Combination Cefepime-Zidebactam (WCK 5222) Tested against Gram-Negative Bacteria Isolated in United States Medical Centers from Patients with Bloodstream Infections. Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington DC, USA
Poster #1598

Frequency and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers During 2018. Lead Author: HS Sader, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #2217

Comparative Antimicrobial Susceptibility of Gram-Negative Bacteria Isolated from Patients with Bloodstream Infections and Pneumonia When Tested against Tazobactam Combinations. Lead author: CG Carvalhaes, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #2192

Ceftolozane-Tazobactam Activity against Difficult-to-Treat Resistance in Pseudomonas aeruginosa from Bloodstream Infections in US Hospitals. Lead author: D Shortridge, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1589

Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin. Lead author: CG Carvalhaes, presented at ID Week 2019, October 2-6, Washington DC, USA
Poster #1583